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Introduction
Breast cancer represents the most common tumor in
women. Recent data show an incidence of 122.9/100.000
(1), with a mean age of 61 years at the time of diagno-
sis. Women aged > 65 years with breast cancer are about
40.9% and incidence rates (SEER 9) increased from
0.32% in 1975 to 0.42% in 2002 (1). The increase in
the incidence rate of breast cancer in older women is re-
lated to two factors: the aging of general population and
the increased use of screening programs. The over sixty,
which in 1980 were 11.3%, in 2030 will represent 20%
of the general population (2, 3).
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SUMMARY: Breast carcinoma in elderly women. Our experien-
ce. 
A. VESTITO, F.F. MANGIERI, G. GATTA, M. MOSCHETTA, B. TURI, 
A. ANCONA
Purpose. To analyze the biological features of breast cancer in wo-
men aged more than 70 years and to evaluate the utility of complete
breast examination in elderly patients.
Patients and methods. In the period between January 2000 and
March 2009, 147.189 women aged more than 39 years underwent
breast examination. In 1.527 diagnosis of breast carcinoma was made.
Patients affected by breast carcinoma were subdivided into two groups
basing on age  (< 70 and ≥ 70 years). The two groups were compared
for tumor size on imaging studies, histology, pT stage, grading and the
presence of estrogen and progesterone receptors.
Results. In comparison with younger women, breast carcinoma in
elderly  presented as invasive ductal form in most of cases (p 0.004), T1
and T2 stages (p 0.0001), G1 grade (p 0.0001) and positive for the
presence of estrogen and progesterone receptors (p <0.0001). 
Conclusions. Basing on the incidence rate and the biological fea-
tures of breast cancer in elderly women without co-morbility, breast
cancer prevention in women is considered useful until the age of 74
years. 
RIASSUNTO: Il carcinoma della mammella nelle donne anziane. No-
stra esperienza.
A. VESTITO, F.F. MANGIERI, G. GATTA, M. MOSCHETTA, B. TURI, 
A. ANCONA
Obiettivo. Analizzare le caratteristiche biologiche dei tumori del-
la mammella e valutare l’utilità del controllo senologico completo in
donne di età ≥70 anni.
Pazienti e metodi. Nel periodo gennaio 2000 - marzo 2009, so-
no stati effettuati 147.189 controlli senologici in donne di età >39 an-
ni. In 1527 casi è stato diagnosticato un carcinoma della mammella.
Le pazienti affette da carcinoma mammario sono state suddivise in due
classi di età (< 70 e ≥ 70 anni). Per le due classi sono state analizzati
e confrontati le dimensioni del tumore all’imaging, l’istotipo, il pT, il
grading, la presenza di recettori per estrogeni e progesterone.
Risultati. Rispetto a soggetti più giovani, il carcinoma della mam-
mella nella paziente anziana si presenta prevalentemente come carci-
noma duttale infiltrante (p 0.004), compreso tra T1 e T2 (p 0.0001),
con basso grading (G1 - p 0.0001) e positività dei recettori per estroge-
ni e progesterone (p<0.0001). 
Conclusioni. In relazione all’incidenza e alle caratteristiche bio-
logiche del tumore della mammella nella donna anziana, si ritiene op-
portuno in assenza di comorbilità il prosieguo dei programmi di pre-
venzione senologica fino a 74 anni.
KEY WORDS:  Breast cancer - Elderly women.
Carcinoma mammario - Donne anziane.
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Numerous studies show that the incidence rate of
breast cancer increases with age (4 - 7). About 50% of
breast carcinomas, in fact, are diagnosed in women > 65
years (3.8 to 10), while the percentage of cancer diagnosed
in women > 70 years ranges from between 30 and 47%
(10,11) and it is expected that in 2035 this percentage
could reach 70% (12). The survival rate of women with
breast cancer over sixty rose from 76.9% in 1975 to
91.7% in 2002 (SEER9) (1) and, to date, it is similar
to that of the general population (13, 14).
Screening programs for the age group from between
50 and 69 years have shown a reduction in mortality in
women up to 69 years (4), but no reported data de-
monstrate the usefulness of further controls in women
≥ 70 years, except for the experience of Tabar (15) whi-
ch includes women up to 74 years. However, the in-
creased life expectancy and the increased incidence of
breast cancer in the general population require careful
evaluation of breast cancer in older women, not only for
the proper treatment planning, but also for the reas-
sessment of the age group to be included in screening
programs.
Therefore, our study aims to analyze the biological
characteristics of breast cancer in women aged ≥ 70 years
and to assess the cost-benefit ratio of the complete brea-
st control in this group of women.
Patients and methods
In the period from January 2000 and March 2009, 147.189 wo-
men aged > 39 years were evaluated at the Breast Unit of Bari,“San
Paolo” Hospital. All women underwent clinical breast examination,
mammography and ultrasound as outpatients, except for women with
mammographic fibro-fatty structure, in which complete ultra-
sound examination was indicated only in selected cases. Clinical brea-
st examination, mammography and ultrasonography were performed
by a breast “dedicated” radiologist.
The mammography equipments used in the course of time were:
analogic GE Alpha RT, Diamond GE and digital Senograf 2000 (GE
Healthcare, Waukesha, Wisconsin, USA). Two projections (cranio-
caudal and oblique) were performed. If necessary, additional scree-
nings were performed in targeted compression and / or direct ra-
diographic magnification. Ultrasonography was performed by AU5,
My Lab 50, 70 X Vision (Esaote, Genoa, Italy) devices, with a mul-
ti-frequency linear array probe (7-14 MHz).
In selected cases, patients underwent MRI and fine-needle aspi-
ration for cytology and/or histological examination. MRI was
performed with a 1.5-T unit (Magnetom Symphony Maestro
Class, Siemens, Forcheim, Germany) using a dedicated breast coil,
with the patient in the prone position. The study protocol included
a transverse T1 localization sequence, a sagittal T2 fat-sat sequence
and a T1 Gre 3D-Flash sequence in order to study the dynamics of
the enhancement, acquiring five series of images on an axial plane
in quick succession, after the intravenous injection of gadobutrol (Ga-
dovist, Bayer) at a dose of 0.1 mmol / kg body weight.
The fine needle aspiration for cytology was performed under ul-
trasound guidance using 21G needle. For the percutaneous micro-
biopsy a digital stereotactic prone table associated with Fischer Mam-
motome® system (Ethicon Endo-Surgery, Breast Care, Norstedlt, Ger-
many) was used. This device allowed the sampling of the lesion with
a 360° mechanical aspiration (23-25 mmHg) . For the sampling, 11G
needles have been used. From between 8 to 18 samples have been
performed, with a mean value of 11. The cores removed were sub-
sequently checked by direct magnification X-ray technique. In the
site of biopsy, a non-magnetic clip was positioned in all cases in or-
der to identify the exact site of sampling.
Among the 147.189 controls, 145.662 were negative, while 1527
resulted positive for malignancy.
In our series, we analyzed: tumor size (<1 cm, 1-1.9 cm, 2-4.9
cm, ≥ 5 cm), histology (ductal carcinoma, lobular, mucinous, tubular,
medullary, other), T (pT0, pT1, pT2, pT3, pT4), grading (G1, G2,
G3), receptors for estrogen and progesterone (ER +, PgR +, E / PgR
+) and the presence of co-morbidities (hypertension, cardiovascular
disease, diabetes).
Patients were divided into two age groups (<70 and ≥ 70 years)
and the main characteristics of cancer were analyzed in women aged
≥ 70 years as compared with those of age <70 years.
Statistical analysis
The chi-square test was used for comparison (StatXact-7 Cytel
Studio Version 7.0.0 - Oct 21, 2005). A p-value <0.005 was consi-
dered statistically significant.
Results
Among the 147.189 patients aged > 39 years who un-
derwent breast full control at our facility, breast cancer
was diagnosed in 1527 (1.04%). Of these, 1.346
(88.2%) were aged < 70 years, 181 (11.8%) ≥ 70 years.
The group of women aged < 70 years included patients
with a wide age range (from 39 to 69 years) and this may
represent a limitation of our study, because it is likely that
biological characteristics of tumor affecting a 65-69 year-
old woman are closer to those of a tumor affecting a wo-
man ≥ 70 years rather than between 40 and 50 years.
Table 1 summarizes tumor characteristics in both
groups. The tumor size detected in the different ima-
ging methods is slightly higher in women over 70; in
fact, 45% of tumors (vs. 39% in women aged <70 years)
has a maximum transverse diameter of between 2 and
4.9 cm, on the contrary , millimetric injuries are more
common in women under 70 (14% vs 7% in older wo-
men). Similar data have been obtained on the size of tu-
mors between 1 and 1.9 cm (38% in women under 70
vs 39% in older women) and a diameter ≥ 5 cm (9%
vs 9%). However, these data are not statistically signi-
ficant (p 0.0728).
With regard to the histological features of tumors, in
both groups, ductal carcinoma (Fig. 1) represents the most
frequent histological type (84% in women aged <70 years
vs 83% in women aged ≥ 70 years). However, the per-
centage of in situ cancers diagnosed in women under 70
is higher (44%) as compared with older women (23%).
The statistically significant difference (p 0.0004) is also
evident in the percentage of invasive carcinoma, which
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has a higher value in older women (60% vs 40% in wo-
men aged ≥ 70 years) (Fig. 2). The distribution of other
histological types (lobular, mucinous, tubular, medullary
carcinoma) is almost similar in both groups, with a sli-
ght predominance of mucinous carcinoma (Fig. 3) in el-
derly women (2% vs 1% in women aged <70 years ) and
medullary carcinoma in women under 70 (2% vs 1% in
the ≥ 70 years).
The analysis of T parameter showed a lower per-
centage of T0 and T1 in women aged ≥ 70 years than
those aged <70 years (a total of T0 + T1 of 45.7% vs
64.5%) and a higher percentage of T2, T3 and T4 in wo-
men older than 70 as compared with women < 70 (a to-
tal of T2 + T3 + T4 of 54.3% vs 35.5%) (Fig. 4). In par-
ticular, in women under 70 a greater number of T0 (2%
vs 1% in the ≥ 70 years) and T1 (62.5% vs 44.7%) was
shown, whereas in older women T2 (42.1% vs 29% in
women aged <70 years), T3 (5.2% vs 3.5%) and T4 (7%
vs 3%) were predominant, with statistically significant
differences (p 0.0001).
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Fig. 1 - Mammography in 71-year old woman. a) Left cranio-caudal mammography
with targeted compression (b), absolutely non specific and performed in the site
of US finding (c), which shows millimetric hypoechoic gap with posterior acou-
stic barrier (C5 US guided cytology). Histological diagnosis: invasive ductal car-
cinoma (T1a, N1a, Mx; G1).
TABLE 1 - DIMENSIONAL, HISTOLOGICAL AND BIOLO-
GICAL CHARACTERISTICS OF BREAST CANCER AND
CO-MORBIDITY IN WOMEN AGED <70 AND ≥ 70 YEARS
TESTED POSITIVE FOR BREAST CONTROL IN THE PE-
RIOD BETWEEN JANUARY 2000 AND MARCH 2009.
*statistically significant
Parameter <70 years ≥70 years p
(%) (%)
Tumor size
<1 188 (14) 13 (7) 0.0728
1-1.9 512 (38) 71(39)
2-4.9 525 (39) 81 (45)
>5 121 (9) 16 (9)
Histology
Ductal 1.130 (84) 150 (83) 0.0004*
Ductal in situ 592 (44) 41 (23) 
Invasive ductal 538 (40) 109 (60)
Lobular 108 (8) 16 (9)
Mucinous 14 (1) 4 (2)
Tubular 13 (1) 2 (1)
Medullar 27 (2) 2 (1)
Other 54 (4) 7 (4)
T
T0 27 (2) 2 (1) 0.0001*
T1 842 (62.5) 81 (44.7)
T2 390 (29) 76 (42.1)
T3 47 (3.5) 9 (5.2)
T4 40 (3) 13 (7)
G
G1 269 (20) 77 (42.5) 0.0001*
G2 599 (44.5) 54 (30)
G3 478 (35.5) 50 (27.5)
Receptors
Pg 538 (40) 140 (77.34) <0.0001*
E+ 1009 (75) 147 (81)
P+ 713 (53) 116 (64)
Comorbidity
Hypertension 161 (12) 42 (23) 0.001*
CV diseases 54 (4) 38 (21)
Diabetes 13 (1) 3 (16)
≥2 diseases 141 (10.5) 40 (22)
Total 
patients 1.527 1.346 (100) 181(100)
Fig. 2 - Distribution of histological types of breast cancer in women aged < 70
and ≥70 years (total number of patients: 1.527).
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The analysis of grading allowed to identify statisti-
cally significant differences between the two groups (p
0.0001). In fact, a lower biological aggressiveness of brea-
st cancer in older women (G1 42.5% vs 20% in women
aged <70 years) (Fig. 5) and a prevalence of G2 and G3
cancers in women under 70 (G2: 44.5% vs 30 % in ≥
70 years; G3: 35.5% vs 27.5%) were found.
The positivity of receptors for estrogen and proge-
sterone is higher in women aged ≥ 70 years. Data were
statistically significant (p <0.0001) and showed not only
a positivity for estrogen and progesterone receptors in
elderly women (77.34% vs 40%), but also a positivity
for individual receptors, respectively, for estrogen (81%
vs 75%) and for progesterone (64% vs 53%).
Any co-morbidity of patients, in particular the pre-
sence of hypertension, cardiovascular disease and diabetes,
was finally analyzed. These diseases were more frequent
in women aged ≥ 70 years than in women aged <70 years
(a total of 80% vs 27.5%, p 0.001).
Discussion
Basing on a review of the literature and the results of
our study, a statistically significant lower biological ag-
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Fig. 4 - Breast imaging in 75-year old woman. a) Right cranio-caudal and obli-
que mammographic projections showing a massive opacity with irregular and
spiculated margins in fibro-fatty breast. b, c) MRI confirms malignant massive
nodular area of inhomogeneous enhancement. d) Corresponding Intensity/time
curve characterized by type III pattern according to Fischer classification. Hi-
stological diagnosis: invasive ductal carcinoma (T3, N2, Mx, G3).
Fig. 5 - Breast imaging and histology in 70-year old woman. a) Right cranio-
caudal mammographic projection showing millimetric undefined opacity; the
targeted compression (b) confirms irregular and inhomogeneous margins. c)
Corresponding ultrasound: inhomogeneous hypoechoic irregular gap in most
vertical axis (US guided cytology C4). Histological diagnosis: invasive ductal
carcinoma (T2, N1, Mx, G1). d) Histological section of breast carcinoma with well-
differentiated tubular architecture, mild nuclear pleomorphism and glandular ele-
ments contained in a stromal elastosic matrix. EE staining; 200x magnification.
Fig. 3 - Breast imaging in 76-year old woman. a) e b) Left mammographic cra-
nio-caudal and oblique projections showing massive opacity with partially un-
defined caudal margins and homogeneous density. c) Corresponding ultrasound:
inhomogeneous hypoechoic nodule with regular and defined margins. Histo-
logical diagnosis: mucinous carcinoma (T1c, N0, M0).
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gressiveness of breast cancer in older women is reported
(3, 7, 13, 16, 17). According to Singh (p 0.86) (16), our
results do not show a significant difference of tumor size
between women under 70 and elderly women (p
0.728); besides, regardless of the lesion size, the biolo-
gical characteristics of the tumor are most favorable in
older women, as compared with those of cancer in post-
menopausal under 70 women (17). 
As reported in literature, the invasive ductal carcinoma
represents the most common cancer in older women (3),
medullary and inflammatory carcinomas are less com-
mon than in women under 70 (16), while the papillary
and mucinous carcinomas occur with increased frequency
in older women (7). In our study, we found a prevalence
of invasive ductal carcinomas in older women (60% vs
40% in women aged < 70 years) and a slight differen-
ce in the frequency of mucinous carcinoma (2% vs 1%
in women aged <70 year - p 0004). 
The grading of breast cancer in women over seventy
is lower as compared with women aged <70 years (p
0.0001, in agreement with other series) (18) and the po-
sitivity rate of estrogen and progesterone receptors is
clearly higher (p <0.0001), as shown by Holmes, Diab,
Gajdos (p <0.0001, p 0.007), and Owusu Bultitude
(3,13,18-20). 
A prevalence of well-differentiated cancers in older
women (p <0.001) was already reported in literature (18). 
However, despite the favorable biological characte-
ristics of breast cancer in women aged ≥ 70 years, the mor-
tality rate is high (10). The possible underlying causes
of this data can be related to the presence of co-morbi-
dity (3, 7, 8, 14, 19), to patient under-treatment (8, 10,
18 - 21), or to the poor sensitivity to the prevention in
women over seventy (5, 7, 8). 
Surgical and adjuvant therapies in the treatment of
carcinoma in older women are effective and well tole-
rated (7) and burdened with minimal toxicity (6), with
a 30-day mortality after surgery of less than 1% (7). The
effectiveness of the treatment varies with age (22) and
therapy can increase the disease-free interval and redu-
ce the symptoms of the disease in advanced stage
(11,23,24). However, in many cases, elderly women with
breast cancer do not receive adequate treatment, probably
because of the coexistence of other pathologies that could
affect the result. Data are not easily confirmed, due to
the non-recruitment of older patients in clinical trials (22). 
It has been shown that prevention of breast cancer re-
duces mortality in women aged between 39 and 69 years
(4), but at the moment data on the effectiveness of the
prevention of breast cancer in women over seventy are
rather controversial ( 4, 6, 25, 26). In fact, while Nystrom
in 1993 (25) stated that the reduction of mortality in wo-
men aged between 70 and 74 years who underwent pe-
riodic breast controls was not significant, Morrow in 1994
(7) showed that the prevention of breast cancer can re-
duce mortality even in the presence of co-morbidities. In
particular, Morrow reported that in women aged between
65 and 69 years, prevention allowed to prolong the sur-
vival of 617 days in healthy patients and 311 days in pa-
tients with heart failure, whereas, in women aged more
than 85, respectively of 178 and 126 days (7). Diab (13)
believes that the role of prevention of breast cancer is li-
mited because the causes of death among women over se-
venty affected by breast cancer are independent of the tu-
mor; on the contrary, McCarthy (26) reports that pre-
vention reduces the mortality even in women > 85 years.
In a paper reported in 2001, Caplan (6) proposed to con-
tinue to check the breast care period in the older women,
despite the unfavorable opinion of the USPSTF (United
States Preventive Service Task Force). Jonnson in 2003
(27) stated that the reduction of mortality in women aged
between 70 and 74 years who underwent periodic con-
trols was not significant. Besides, Galit in 2007 (28) stres-
sed that prevention programs allow early diagnosis and
reduce mortality of patients and Bagdwell in 2008 (29)
reported that prevention programs reduce mortality, but
do not alter survival in women aged ≥ 80 years, especially
in the absence of significant co-morbidity. In 2009, Nel-
son (4) confirmes that data on the benefits of breast can-
cer prevention in women aged > 70 years are to date in-
sufficient. Unlike Nelson (4), Diab (13), Nystrom (25) and
Jonnson (27), who consider inefficient to prevent breast
cancer in older women, many other authors (7,26,28 , 29)
believe that screening for breast cancer in older women can
reduce mortality. In fact, the participation of older women
to prevention programs is rather low (56.7% women > 70
years vs 71.1% women aged < 70 years) and diagnosis of
breast cancer is late in this group of patients (12). 
We believe that by encouraging the participation of
women over seventy to programs of prevention, it is pos-
sible to increase the survival rate, as shown by Morrow
(7), especially in the absence of co-morbid factors. It has
been shown that a woman of 70 years has a life expec-
tancy of 15.5 years (11) and, according to Holmes and
Kimmick (3, 9), a woman with a life expectancy of more
than 5 years should continue to conduct examinations
for early diagnosis of breast cancer. Thus, theoretically,
a woman should continue to check until the age of 80
years. However, McPherson (14) shows that in case of
severe co-morbidity, the efficacy of screening program
is reduced and the mortality from breast cancer is reduced
in the large elderly (> 85 years) as compared with elderly
patients (75-84 years) (30). 
Conclusions
Despite the small percentage of in situ tumors, as com-
pared with invasive forms, low T (staging) and G (gra-
ding) stages and the increased breast cancer positivity for
415
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estrogen and progesterone receptors in older women as
compared with younger patients represent statistically si-
gnificant data (p <0.005). These data allow to affirm that
in women over seventy, as compared with women aged
< 70 years, breast cancer is biologically less aggressive.
For these reasons, given the life expectancy in the ab-
sence of co-morbidity, we propose the prevention of brea-
st cancer even in the range of over 70 years and the ex-
tension of breast screening every two years to 70 – 74
year old women, with any subsequent clinical-instru-
mental monitoring every 2 - 3 years in the absence of co-
morbidity.
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